An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism
Autism
About this trial
This is an interventional treatment trial for Autism
Eligibility Criteria
Inclusion Criteria: Meet DSM-IV, ADI, or ADOS criteria for autism spectrum disorder. Age 18-50. Be seen as outpatients IQ>80 5. Demonstrate capacity to provide authorized informed consent or provide consent for participation by an approved surrogate on the autistic individual's behalf Exclusion Criteria: Subjects who are pregnant or nursing mothers. Sexually active women of childbearing potential who are not using adequate birth control measures. Subjects with epilepsy. Subjects with a history of schizophrenia, schizoaffective disorder or other Axis 1 mental disorders, such as bipolar disorder. Subjects reporting history of encephalitis, phenylketonuria, tuberous sclerosis, fragile X syndrome, anoxia during birth, neurofibromatosis, hypomelanosis, hypothyroidism, Duchenne muscular dystrophy, and maternal rubella Subjects who have received depot neuroleptic medication, or other psychoactive drugs within the past 5 weeks. Subjects with renal or liver disease or abnormalities in blood chemistry. Any metallic prosthesis such as plates, pins and screws, shrapnel, metallic foreign body, vascular or neurosurgical clips that may be incompatible with the MRI and any electrical devices such as a pacemaker or a defibrillator Claustrophobia
Sites / Locations
- Mount Sinai School of Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Pitocin
Placebo